MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience
Table 1
Summary of MammaPrint risk assessments.
Total
MP high risk (%)
MP low risk (%)
QNS (%)
Total, unique
54
33 (61%)
7 (13%)
14 (26%)
3 LNs positive
4
4 (100%)
0
0
MP indicated tumors*
50
29 (58%)
7 (14%)
14 (28%)
1 cm max diameter
8
1 (12%)
0
7 (88%)
0 positive LNs†
34
19 (56%)
4 (12%)
11 (32%)
1–3 positive LNs†
15
9 (60%)
3 (20%)
3 (20%)
ER+, PR+, HER2+
2
2 (100%)
0
0
ER−, PR−, HER2+
4
3 (75%)
1 (25%)
0
ER+, PR+, HER2−
29
16 (55%)
4 (14%)
9 (31%)
ER−, PR−, HER2−
6
5 (83%)
0
1 (17%)
ILC
4
1 (25%)
0
3 (75%)
IDC
46
28 (61%)
7 (15%)
11 (24%)
Caucasian
35
22 (63%)
2 (6%)
11 (31%)
Non-Caucasian
15
7 (47%)
5 (33%)
3 (20%)
OncotypeDx low risk
9
3 (33%)
2 (22%)
4 (44%)
OncotypeDx intermediate risk
5
3 (60%)
0
2 (40%)
MP: MammaPrint; QNS: quantity not sufficient; LN: lymph node; ER: estrogen receptor status by IHC; PR: progesterone receptor status by IHC; HER2: HER2-neu receptor status by IHC/FISH; ILC: invasive lobular carcinoma; IDC: invasive ductal carcinoma.
*MP indicated in current international guidelines for stage 1 or 2, ER+ or − invasive breast cancer 5 cm in maximum diameter with 3 LNs tumor positive. †One core biopsy specimen was not subsequently assessed for lymph node status.
